Skip to main content
Vivanza Biosciences Limited logo

Vivanza Biosciences Limited — Investor Relations & Filings

Ticker · 530057 ISIN · INE984E01035 LEI · 984500C0D8S953808867 BSE.NS Wholesale and retail trade
Filings indexed 1 across all filing types
Latest filing 2026-05-09 Annual Report
Country IN India
Listing BSE.NS 530057

About Vivanza Biosciences Limited

https://www.vivanzabiosciences.com

Vivanza Biosciences Limited specializes in the trading, marketing, and distribution of a diverse range of pharmaceutical products and healthcare solutions. The company’s core operations involve the procurement and supply of generic formulations, active pharmaceutical ingredients (APIs), and specialized medical devices. By leveraging an extensive network of manufacturers and suppliers, the organization facilitates the availability of essential medicines across various therapeutic segments. Its portfolio encompasses a wide array of products designed to meet the requirements of global healthcare providers, including surgical equipment and diagnostic tools. The company focuses on maintaining rigorous quality standards and optimizing supply chain logistics to ensure the efficient delivery of healthcare products to international markets. Through strategic partnerships and a commitment to the life sciences sector, the firm aims to bridge the gap between pharmaceutical production and patient access to affordable medical treatments.

Recent filings

Filing Released Lang Actions
In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed copy of newspaper advertisement published in English daily ....
Annual Report Classification · 95% confidence The document contains multiple references to audited financial results for the quarter and financial year ended March 31, 2026, approved by the Board of Directors. It mentions the audit report and financial results being posted on the company's website, consistent with a formal financial reporting process. The document includes detailed financial data and audit information rather than just an announcement or a brief summary. The presence of standalone and consolidated financial results, audit reports, and board approval indicates this is a comprehensive annual financial report. Therefore, the document fits the definition of an Annual Report (10-K) rather than a mere announcement or a regulatory filing. The document length (12,748 characters) supports it being a full report rather than a short notice or announcement.
2026-05-09 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.